BIOMAT Database Logo BIOMAT Database Logo

The renin-angiotensin system in central nervous system tumors and degenerative diseases. 2021

Simon Haron, and Ethan J Kilmister, and Paul F Davis, and Stanley S Stylli, and Theo Mantamadiotis, and Andrew H Kaye, and Sean R Hall, and Swee T Tan, and Agadha C Wickremesekera
Department of Neurosurgery, Wellington Regional Hospital, 6242 Wellington, New Zealand.

Despite their differences, central nervous system (CNS) tumors and degenerative diseases share important molecular mechanisms underlying their pathologies, due to their common anatomy. Here we review the role of the renin-angiotensin system (RAS) in CNS tumors and degenerative diseases, to highlight common molecular features and examine the potential merits in repurposing drugs that inhibit the RAS, its bypass loops, and converging signaling pathways. The RAS consists of key components, including angiotensinogen, (pro)renin receptor (PRR), angiotensin-converting enzyme 1 (ACE1), angiotensin-converting enzyme 2 (ACE2), angiotensin I (ATI), angiotensin II (ATII), ATII receptor 1 (AT1R), ATII receptor 2 (AT2R) and the Mas receptor (MasR). The RAS is integral to systemic and cellular pathways that regulate blood pressure and body fluid equilibrium and cellular homeostasis. The main effector of the RAS is ATII which exerts its effect by binding to AT1R and AT2R through two competitive arms: an ACE1/ATII/AT1R axis, which is involved in regulating oxidative stress and neuroinflammation pathways, and an ATII/AT2R and/or ATII/ACE2/Ang(1-7)/MasR axis that potentiates neuroprotection pathways. Alterations of these axes are associated with cellular dysfunction linked to CNS diseases. The generation of ATII is also influenced by proteases that constitute bypass loops of the RAS. These bypass loops include cathepsins B, D and G and chymase and aminopeptidases. The RAS is also influenced by converging pathways such as the Wnt/β-catenin pathway which sits upstream of the RAS via PRR, a key component of the RAS. We also discuss the co-expression of components of the RAS and markers of pluripotency, such as OCT4 and SOX2, in Parkinson's disease and glioblastoma, and their potential influences on transduction pathways involving the Wnt/β-catenin, MAPK/ERK, PI3K/AKT and vacuolar (H+) adenosine triphosphatase (V-ATPase) signaling cascades. Further research investigating modulation of the ACE1/ATII/AT1R and ACE2/Ang(1-7)/MasR axes with RAS inhibitors may lead to novel treatment of CNS tumors and degenerative diseases. The aim of this review article is to discuss and highlight experimental and epidemiological evidence for the role of the RAS, its bypass loops and convergent signaling pathways in the pathogenesis of CNS tumors and degenerative diseases, to direct research that may lead to the development of novel therapy.

UI MeSH Term Description Entries
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000090862 Neuroinflammatory Diseases Diseases characterized by inflammation of the nervous tissue. Neuroinflammation,Neuroinflammatory Disorders,Disease, Neuroinflammatory,Disorder, Neuroinflammatory,Neuroinflammations,Neuroinflammatory Disease,Neuroinflammatory Disorder
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D016543 Central Nervous System Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges. CNS Neoplasm,CNS Neoplasms,Central Nervous System Neoplasm,Central Nervous System Tumor,Neoplasms, Central Nervous System,Primary Central Nervous System Neoplasm,Central Nervous System Neoplasms, Primary,Central Nervous System Tumors,Primary Central Nervous System Neoplasms,Tumors, Central Nervous System,Neoplasm, CNS,Neoplasms, CNS

Related Publications

Simon Haron, and Ethan J Kilmister, and Paul F Davis, and Stanley S Stylli, and Theo Mantamadiotis, and Andrew H Kaye, and Sean R Hall, and Swee T Tan, and Agadha C Wickremesekera
The renin-angiotensin system and the central nervous system.
April 1977, Federation proceedings,
Simon Haron, and Ethan J Kilmister, and Paul F Davis, and Stanley S Stylli, and Theo Mantamadiotis, and Andrew H Kaye, and Sean R Hall, and Swee T Tan, and Agadha C Wickremesekera
The renin-angiotensin system in the mammalian central nervous system.
August 2005, Current protein & peptide science,
Simon Haron, and Ethan J Kilmister, and Paul F Davis, and Stanley S Stylli, and Theo Mantamadiotis, and Andrew H Kaye, and Sean R Hall, and Swee T Tan, and Agadha C Wickremesekera
Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19.
January 2021, Current medicinal chemistry,
Simon Haron, and Ethan J Kilmister, and Paul F Davis, and Stanley S Stylli, and Theo Mantamadiotis, and Andrew H Kaye, and Sean R Hall, and Swee T Tan, and Agadha C Wickremesekera
[Degenerative diseases of the central nervous system].
September 1959, Rivista sperimentale di freniatria e medicina legale delle alienazioni mentali,
Simon Haron, and Ethan J Kilmister, and Paul F Davis, and Stanley S Stylli, and Theo Mantamadiotis, and Andrew H Kaye, and Sean R Hall, and Swee T Tan, and Agadha C Wickremesekera
[Effects of renin-angiotensin system in the central nervous system].
March 2005, Nihon rinsho. Japanese journal of clinical medicine,
Simon Haron, and Ethan J Kilmister, and Paul F Davis, and Stanley S Stylli, and Theo Mantamadiotis, and Andrew H Kaye, and Sean R Hall, and Swee T Tan, and Agadha C Wickremesekera
[Neurotransmitters and degenerative diseases in the central nervous system].
January 1986, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics,
Simon Haron, and Ethan J Kilmister, and Paul F Davis, and Stanley S Stylli, and Theo Mantamadiotis, and Andrew H Kaye, and Sean R Hall, and Swee T Tan, and Agadha C Wickremesekera
[Ubiquitin and degenerative diseases of the central nervous system].
January 1992, Revue neurologique,
Simon Haron, and Ethan J Kilmister, and Paul F Davis, and Stanley S Stylli, and Theo Mantamadiotis, and Andrew H Kaye, and Sean R Hall, and Swee T Tan, and Agadha C Wickremesekera
[Degenerative diseases of the central nervous system in childhood].
April 1972, Die Medizinische Welt,
Simon Haron, and Ethan J Kilmister, and Paul F Davis, and Stanley S Stylli, and Theo Mantamadiotis, and Andrew H Kaye, and Sean R Hall, and Swee T Tan, and Agadha C Wickremesekera
Renin-angiotensin system in the central nervous system: focus on Huntington's disease.
October 2023, Neural regeneration research,
Simon Haron, and Ethan J Kilmister, and Paul F Davis, and Stanley S Stylli, and Theo Mantamadiotis, and Andrew H Kaye, and Sean R Hall, and Swee T Tan, and Agadha C Wickremesekera
Editorial: The Role of the Renin-Angiotensin System in the Central Nervous System.
January 2021, Frontiers in neuroscience,
Copied contents to your clipboard!